Thursday, March 6, 2025 | 11 AM ET
Presented by
Stuart K. Williams, PhD
The transition of adipose cell-based therapies to treat human and animal diseases is requiring more in depth knowledge of the cells in fat and their therapeutic mechanisms of action. This webinar will explore the emergence of adipose cell based therapies starting with the discovery of the complexity of cells found in fat and how these cells are characterized. The evolution of terminology used to define adipose derived cells has resulted in confusion and misrepresentation. A unified terminology will be presented. The second part of this presentation will explore how we have developed an understanding of mechanism of action of adipose cells and how we determine the potency of a cell isolated and establish dosing. Regulatory issues will be discussed including how these adipose derived cell products are prepared and used following US regulations and guidelines.
The webinar will use the Zoom meeting platform and not the webinar platform. This will enable direct communication between the meeting participants. The total number of participants at this meeting will be limited to 100 individuals.
Auto Subscribe to Webinars
If you would like to be automatically subscribed to all future webinars, please submit your email below.
Meet the Presenter
Stuart K. Williams, PhD
Scottsdale, AZ
cvregen@gmail.com
Dr. Stuart Williams received his Ph.D. in Cell Biology from the University of Delaware, followed by postdoctoral training in Pathology at the Yale School of Medicine. During the period 1980 to 1990 he held a faculty appointment at Jefferson Medical College where he was Director of Research in the Department of Surgery. In 1990, Dr. Williams joined the faculty at the University of Arizona and founded the University of Arizona Biomedical Engineering Program creating a research and educational link between the Medical School and College of Engineering. He held faculty positions jointly in Biomedical Engineering, Surgery, Physiology, and Materials Science and Engineering.
In 2007, Dr. Williams was selected as the Scientific Director and then Executive Director of the Cardiovascular Innovation Institute, a partnership between Jewish Hospital and the University of Louisville in Louisville Kentucky. From 2021 to 2023 he served as the executive Vice President of Technology Development at Orgenesis. Dr. Williams’ research interests have focused on medical devices and regenerative medicine. He developed and patented the first methods to use fat-derived stem and regenerative cells for therapeutic use. He established the Bioficial Organs Program to create human tissues and organs for clinical therapeutics. Central to this effort is the use of adipose derived stem and regenerative cells and development of 3D bioprinting technologies. Dr. Williams has authored over 350 scientific publications. His entrepreneurial spirit has resulted in 32 issued US patents with numerous patents pending. He has founded four biotechnology companies; maintained active managerial positions and has been an active consultant to the medical device, regenerative medicine and pharmaceutical community. He is a Fellow of the American Heart Association and a Fellow of the American Institute of Medical and Biological Engineering. Dr. Williams’ primary residence is in North Scottsdale, Arizona.